Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 240 for:    (armodafinil)

Modafinil's Effects on Cognition in Remitted MDD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03620253
Recruitment Status : Terminated (Principal Investigator left study site)
First Posted : August 8, 2018
Last Update Posted : August 8, 2019
Sponsor:
Collaborators:
Ontario Ministry of Health and Long Term Care
The Canadian Biomarker Integration Network in Depression
Information provided by (Responsible Party):
Shane McInerney, St. Michael's Hospital, Toronto

Tracking Information
First Submitted Date  ICMJE July 27, 2018
First Posted Date  ICMJE August 8, 2018
Last Update Posted Date August 8, 2019
Actual Study Start Date  ICMJE October 15, 2018
Actual Primary Completion Date August 6, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 2, 2018)
Cognition [ Time Frame: 8 weeks ]
Cognition will be measured using a Neurocognitive Index, which will be calculated using the CNS Vital Signs Neurocognitive Battery (a computer program). The domains tested within the cognitive battery include composite memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, and processing speed. The Neurocognitive Index is based on a composite, average score of the scores on these 6 domains. From the Neurocognitive Index score, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 85.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03620253 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 2, 2018)
  • Composite Memory [ Time Frame: 8 weeks ]
    This is a measure of how well participants can recognize, remember, and retrieve words and images. Composite memory will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 103.
  • Psychomotor Speed [ Time Frame: 8 weeks ]
    This is a measure of how well a participant is able to perceive, attend, and respond to complex visual-perceptual information and perform simple, fine motor coordination. Psychomotor speed will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 93.
  • Reaction Time [ Time Frame: 8 weeks ]
    This is a measure of how quickly a participant can react to simple and complex direction sets. Reaction time will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 107.
  • Complex Attention [ Time Frame: 8 weeks ]
    This is a measure of a participant's ability to track and respond to multiple stimuli over long periods of time, and perform complex mental tasks quickly and accurately. Complex attention will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 56.
  • Cognitive Flexibility [ Time Frame: 8 weeks ]
    This is a measure of how well a participant can adapt to rapidly changing and complex directions, and manipulate information. Cognitive flexibility will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 63.
  • Processing Speed [ Time Frame: 8 weeks ]
    This is a measure of a participant's ability to recognize and process information. Processing speed will be measured based on performance on a series of tests in the CNS Vital Signs Neurocognitive Battery (a computer program). Based on performance, the CNS Vital Signs program classifies the participant as above, average, low average, low, or very low based on their deviation from a standard score of 79.
  • Subjective Cognitive Improvement [ Time Frame: 8 weeks ]
    This is a measure of how well the participant feels their cognition has improved after using the study drug. This will be measured using the British Columbia Cognitive Complaints Inventory, a 6-item screening tool that assesses perceived cognitive difficulties in patients with MDD over the past 7 days. A total score between 0 and 18 is calculated based on participant self-report, where a higher score represents greater cognitive impairment.
  • Functional Disability [ Time Frame: 8 weeks ]
    This will be assessed using the Sheehan Disability Scale, which assesses functional impairment in work/school, social life, and family life. This is scored based on a self-report scale of 0-10 in 3 domains: work/school, social life, and family life/home responsibilities. A total score between 0 and 30 is calculated based on the sum of these 3 domains. Higher values represent greater disability.
  • Work Productivity [ Time Frame: 8 weeks ]
    This will be assessed using the Lam Employment and Productivity Scale, a brief questionnaire designed to assess occupational productivity.This is scored based on a self-report scale from 0-4 in 7 domains: low energy or motivation, poor concentration or memory, anxiety or irritability, getting less work done, doing poor quality work, making more mistakes, and having trouble getting along with people or avoiding them. A total score between 0 and 28 is calculated as a sum of all sub scores. Higher values represent greater impairment.
  • Motivation and Energy [ Time Frame: 8 weeks ]
    This is be assessed using the Motivation and Energy Inventory, an 18-item inventory to measure changes in lassitude and energy with antidepressant treatment. Based on self-report measurements, a total score between 0-108 is determined, where a lower score corresponds to lower levels of motivation and energy.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: August 2, 2018)
  • Overall Quality of Life [ Time Frame: 8 weeks ]
    This will be assessed using the World Health Organization Quality of Life, Shortened Version. A score between 4 and 20 is determined for four domains: physical health, psychological health, social relationships, and environment. A total score for overall quality of life between 16 and 80 is then calculated as the sum of these four domain scores. A higher score represents greater quality of life.
  • Life Enjoyment and Satisfaction [ Time Frame: 8 weeks ]
    This is measured using the Quality of Life Enjoyment and Satisfaction Questionnaire, a depression-specific quality of life measure. This questionnaire is scored using 8 domains: physical health/activities (possible score between 13-65), feelings (total score between 14-70), work (total score between 13-65), household duties (total score between 10-50), school/course work (total score between 10-50), leisure time activities (total score between 6-30), social relations (total score between 11-55), and overall satisfaction (total score between 12-60). Lower scores represent lower levels of enjoyment and satisfaction.
  • Sleepiness [ Time Frame: 8 weeks ]
    This will be assessed using the Epworth Sleepiness Scale, an 8-item scale used as a subjective measure of a patient's sleepiness. A total score between 0 and 24 is calculated based on the participant's self-report, where higher scores represent greater sleepiness.
  • Fatigue [ Time Frame: 8 weeks ]
    This will be assessed using the Fatigue Severity Scale, a 9-item questionnaire with questions related to how fatigue interferes with certain activities. A total score between 9 and 63 is calculated based on the participant's self-report, where higher scores represent greater levels of fatigue.
  • Sleep Quality [ Time Frame: 8 weeks ]
    This will be assessed using the Pittsburgh Sleep Quality Index, which assesses night-time sleep problems, focusing on sleep experiences over the past month. A total score between 0 and 21 is assigned, where higher scores represent worse sleep quality.
  • Depressive Symptomatology [ Time Frame: 8 weeks ]
    This will be assessed using 2 measures. The first is the Quick Inventory of Depressive Symptomatology, a 6-item measure of MDD symptom severity; a total score between 0-27 is possible for this questionnaire based on participant self-report. The second measure is the Montgomery-Asberg Depression rating scale, a clinician-administered 10-item scale that incorporates symptoms most sensitive to change; a total score of 0-60 is possible. Both of these scores will be converted to percentages (i.e. participant score divided by total possible score) and then averaged to get a final percentage representing depressive symptoms. A higher score represents a higher degree of depressive symptoms.
  • Anxiety Symptomatology [ Time Frame: 8 weeks ]
    Th is measured using the Generalized Anxiety Disorder 7-Item, an anxiety scale used for assessing anxiety severity. A total score is calculated based on 7 questions (each of which are self-rated on a scale of 0 to 3) for a total score between 0 and 21. Higher scores represents a higher degree of anxiety symptoms.
  • Psychiatric Symptomatology [ Time Frame: 8 weeks ]
    This will be assessed using the Brief Symptom Inventory-53, which assesses the psychological profile of an individual covering somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. A global severity index is determined as the mean score on the 53 questions on this inventory. Each question is self-rated by the participant on a scale of 0 to 4, and a total score of 0 to 4 is possible for the global severity index. A higher score represents a higher degree of psychiatric symptoms.
  • Treatment Satisfaction (with study drug) [ Time Frame: 8 weeks ]
    This will be assessed by administering the Abbreviated Treatment Satisfaction Questionnaire for Medication, a 9-item questionnaire evaluating patient satisfaction with medication treatment in a study. A total score of 9 to 59 is possible, where higher scores represent greater treatment satisfaction.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Modafinil's Effects on Cognition in Remitted MDD
Official Title  ICMJE Does Modafinil Have Pro-cognitive Effects in Those With Residual Cognitive Impairment Despite Remitted Depression?
Brief Summary Cognitive difficulties such as indecisiveness or inability to concentrate are core symptoms of depression with up to 90% of untreated depressed individuals experiencing these symptoms. As many as half of those who remit from a major depressive episode continue to experience residual cognitive deficits, but these symptoms are frequently overlooked in clinical practice. This leads to persistent cognitive deficits which can cause reduced level of functioning and loss of productivity. As standard antidepressants have an inadequate impact on these residual cognitive symptoms, further treatment options are required. Modafinil is a wakefulness agent with evidence that it improves some domains in cognition such as memory in those whose non-cognitive depressive symptoms have been treated over a short term period. This medication may have favourable lasting effects on cognition, such as the ability to plan and execute tasks in those who receive modafinil for a longer time period. The aim of this study is to investigate whether modafinil can enhance cognition and have additional effects on functioning and work productivity in a sample of participants who were treated for depression but who continue to experience cognitive deficits.
Detailed Description

Background:

Major Depressive Disorder (MDD) is a chronic mental disorder with a lifetime prevalence of 5-20% (Kessler et al., 2003; Woo et al., 2016). While depressed mood and loss of interest in activities are core features of MDD, cognitive deficits such as indecisiveness and inattention are present and interfere with work and social functioning (McIntyre et al., 2013). These cognitive deficits frequently persist beyond remission from a Major Depressive Episode (MDE), with up to 94% of those impaired during an episode continuing to experience deficits after the episode (Bhalla et al., 2006), including deficits in attention, executive functioning, and psychomotor speed (Salagre et al., 2017). These residual cognitive symptoms often persist and are associated with poor functioning and loss of productivity (Lam et al., 2014).

In a systematic review examining MDD patients in remission, multiple regression analyses found that MDD predicted lower performance on measures of attention, processing speed, and cognitive flexibility relative to healthy controls (HCs; Hasselbalch et al., 2011). Further evidence for the presence of neuropsychological deficits in remitted MDD patients comes from a systematic review and meta-analysis that found the remitted MDD patient group had executive function and attentional deficits, while symptomatic patients exhibited executive function, attentional, and memory deficits (Roc et al., 2013).

Importantly, there are no medications with evidence to modify cognition in remitted depression. This suggests that in order to assist in the recovery of cognitive and functional abilities, additional novel treatment options are required.

There is considerable evidence that subjective and objective measures of cognition are not well correlated in MDD. This has informed the investigators' choice of separate subjective and objective measures for this study. In addition, cognitive disturbances affect psychosocial function and quality of life across several areas, and this necessitated measurement of quality of life. In this study, the investigators will use a computerized version of the Central Nervous System (CNS) Vital Signs Cognitive Battery, which will provide a Neurocognitive Index score (NCI). The NCI is a global measure of cognitive functioning, averaging the scores from 7 tests over 5 domains: composite memory, psychomotor speed, reaction time, complex attention, and cognitive flexibility.

Pilot results from the The Canadian Biomarker Integration Network in Depression (CAN-BIND)-1 study, involving treatment with escitalopram, have clearly documented the nature of deficits, and are in line with expectations in remitted depression. In this pilot sample of 208 participants, 15% of participants had global cognitive impairment despite 8 weeks of antidepressant treatment and achievement of clinical remission (McInerney, personal communication).

In an 8-week antidepressant study, those who significantly improved in global cognitive functioning (assessed using NCI) had superior functioning and work productivity relative to those who did not significantly improve (Hasselbalch et al., 2011). Vortioxetine is the only antidepressant with modest evidence for improving cognitive parameters during a depressive episode (Rock et al., 2013). Research into the use of psychostimulants as a treatment for cognitive deficits in depressed patients has led to the consideration of modafinil and methylphenidate as potential novel pharmacological treatments (Minzenberg et al., 2008). Modafinil is a well-tolerated wakefulness agent where only two clinical studies have previously examined its role on cognition in depression; one where currently depressed patients had improvements in one measure of executive function after 4 weeks of treatment as an adjuvant (DeBattista et al., 2004), and the other where there were improvements in memory after a single dose in depressed participants who achieved remission (Kaser et al., 2016). Unlike methylphenidate, modafinil appears to impact both "hot" (emotion-laden) and "cold" (independent of emotion) cognitive deficits, which are commonly seen in remitted depression.

Immediate effects of modafinil on cognition have been shown (Kaser et al., 2016) and the investigators will be the first to examine the pro-cognitive effects in a remitted depressed sample over 8 weeks. The dose of modafinil (200mg) used in the study, sample size, and randomized control trial (RCT) study design parallels those described in the immediate effect study, and this maintains continuity. However, the study does not examine whether the immediate effects are maintained. More importantly, it is unclear whether the cognitive improvements translate into improvement in functioning.

The added focus on functional outcomes fits with patient-centered models of healthcare, as functional outcomes are of greatest importance to most patients. Thus, the RCT study and choice of outcome variables have been carefully designed with specific endpoints to delineate these aspects. Cognitive flexibility, memory, and attention will be domains of importance in this study, since these domains have been shown in previous literature to be improved by modafinil (Minzenberg et al., 2008; DeBattista et al., 2004; Kaser et al., 2016).

Objectives, Hypotheses, and Impact:

The primary objective of this study is to delineate the cognitive effects of modafinil in patients with remitted depression at baseline and 4 weeks, and monitor whether these effects are maintained with continual dosage over an 8-week period. The secondary objective of this study is to understand the effect of modafinil in patients with remitted depression on measures of functioning at baseline, 4 weeks, and 8 weeks, and whether these effects parallel the cognitive changes.

The investigators' overarching hypothesis is that specific aspects of cognitive functioning, including the domains of memory, attention, and cognitive flexibility, will improve through treatment with modafinil. The investigators hypothesize that participants with remitted depression who continue to experience cognitive deficits and are taking modafinil will have improvements in aspects of cognitive domains at 4 weeks, and these improvements will be sustained at 8 weeks. It is also hypothesized that functional improvements will parallel the improvements in cognitive domains.

The study ensures a closer examination of modafinil's effect on individual facets of cognition in patients with remitted MDD. This enhanced understanding will enable the development of new treatment plans for residual cognitive symptoms, where none currently exist. Moreover, it could spur interest in new drug development programs to address an unmet need of targeting cognition across disorders where depression is a central feature (e.g. Bipolar Disorder, Generalized Anxiety Disorder). Finally, the study would delineate the specific endophenotypes within cognition (e.g. working memory) and functional improvement (e.g. social functioning), which would lead to personalized treatment options based on the endophenotype profile.

Methods In this randomized control trial, remitted MDD patients with residual cognitive deficits (n=50) will have cognitive symptoms and functioning evaluated before and after an 8-week trial of modafinil 200mg or placebo. Participants will be recruited through the ongoing CAN-BIND 1 Wellness Study; the Depression Program at St. Michael's Hospital; the shared care network at St. Michael's Hospital; and referrals from residents, family doctors, and other St. Michael's psychiatrists. All participants who meet inclusion criteria will be asked to enrol in this study and provide written informed consent.

Participants will be on a stable dose of an antidepressant for at least 6 months prior to enrolment. They will be required to remain on this stable dose for the duration (8 weeks) of the trial. They will be prescribed modafinil or placebo at a dose of 100 mg for the first week then 200mg for 7 weeks. After week 8, participants will be informed of which group they were in and if they were taking modafinil, they can choose to continue on modafinil or to discontinue.

Participants will undergo an 8-week randomized, placebo controlled treatment trial of modafinil 200mg with a total of 3 study visits. Participants may require more clinical visits as needed. Screening will be done to confirm study eligibility. At the screening visit all participants will provide demographic data (age, gender, education, ethnicity, occupation, family history of mental illness), undergo a structured diagnostic assessment (Mini-International Neuropsychiatric Interview), complete the CNS Vital Signs cognitive battery, and have the Montgomery-Asberg Depression Rating Scale administered. At the baseline visit, participants will initiate the study drug trial, complete clinician rated and self-report scales, and complete the cognitive battery in CNS Vital Signs. Participants will start with a 100 mg dose at baseline, and increase to the 200 mg dose at week 1 if the drug is well tolerated. Participants will repeat all measures at week 4 and 8. Adverse events will be recorded at each study visit. For participants who wish to discontinue the study drug at week 8, they will first have their dose decreased to 100 mg for one week and attend an additional week 9 safety visit to evaluate adverse events before full discontinuation of the study drug.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
50 Participants (aged 18-55) who are experiencing cognitive deficits (measured as Neurocognitive Index >1 standard deviation below the mean) despite remission from depression (Montgomery-Asberg Rating Scale for Depression (MADRAS) score <7) will be eligible to receive modafinil (100-200mg daily) or two identical placebo capsules each morning for a period of 8 weeks.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
25 participants will be randomly assigned to the modafinil treatment group, and 25 to the placebo group. The drug/placebo will be randomized and dispensed by the research pharmacy at St. Michael's Hospital. A research technician who is blind to the study will prepare the capsules and break the blind at the end of the study.
Primary Purpose: Treatment
Condition  ICMJE
  • Major Depressive Disorder
  • Cognitive Impairment
Intervention  ICMJE
  • Drug: Modafinil
    Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
    Other Names:
    • Provigil
    • Alertec
    • 2-benzhydrylsulfinylacetamide
  • Drug: Placebo
    Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study Arms  ICMJE
  • Experimental: Modafinil
    Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
    Intervention: Drug: Modafinil
  • Placebo Comparator: Placebo
    Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 6, 2019)
9
Original Estimated Enrollment  ICMJE
 (submitted: August 2, 2018)
50
Actual Study Completion Date  ICMJE August 6, 2019
Actual Primary Completion Date August 6, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Diagnostic and Statistical Manual (DSM)-5 criteria for past Major Depressive Episode within MDD, confirmed through Mini-International Neuropsychiatric Interview (MINI) diagnosis
  2. Age between 18 and 55 years
  3. Montgomery-Åsberg Depression Rating Scale < 7 (in remission)
  4. Ability to read and understand English
  5. Participant has been treated with an antidepressant for ≥ 6 months prior to enrolment
  6. Participant agrees to remain on a stable antidepressant regimen for the duration of the trial (8 weeks)
  7. Participant is currently experiencing cognitive deficits, as confirmed by an NCI >1 standard deviation below the mean on CNS Vital Signs cognitive battery
  8. Women of child bearing potential must agree to use birth control for the duration of the study and 1 month following discontinuation of the study drug

Exclusion Criteria:

  1. Pregnancy/lactation
  2. Lifetime history of Bipolar I, II or psychosis; other comorbidities (e.g. Generalized Anxiety, Panic Disorder) may be allowed by clinician judgement
  3. Subject has current clinical diagnosis of autism, dementia, intellectual disability, or mild cognitive impairment
  4. Meets DSM-5 criteria for active Post-Traumatic Stress Disorder, confirmed through MINI diagnosis
  5. Subject meets criteria for current personality disorder
  6. Concomitant use of monoamine oxidase inhibitors and/or other psychotropic drugs including lithium, clomipramine, and triazolam
  7. Recent (< 6 months) stimulant use, such as medications used for attention deficit hyperactivity disorder
  8. Subject is taking antipsychotics
  9. Subject is taking herbaceuticals (i.e. natural products that have psychoactive properties, such as St. John's wort)
  10. Concomitant use of medications that may interact with modafinil, including warfarin and cyclosporine
  11. Medical condition requiring immediate investigation or treatment
  12. Recent (< 6 months)/current history of drug abuse/dependence (other than caffeine or nicotine)
  13. Previous intolerance or failure to respond to an adequate trial of modafinil
  14. Any past history of head injury or concussion, as confirmed by the Ohio State University Traumatic brain injury (TBI) Identification Short Form
  15. Current suicidal ideation (MADRS Item 10 ≤2 or by clinician judgement)
  16. History of coronary artery disease, recent (<1 year) myocardial infarction, or unstable angina
  17. History of left ventricular hypertrophy, ischemic ECG changes, chest pain, arrhythmia, or clinically significant manifestations of mitral valve prolapse in association with use of CNS stimulants
  18. Involvement in another treatment study during the time of the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03620253
Other Study ID Numbers  ICMJE MOCOG-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Shane McInerney, St. Michael's Hospital, Toronto
Study Sponsor  ICMJE St. Michael's Hospital, Toronto
Collaborators  ICMJE
  • Ontario Ministry of Health and Long Term Care
  • The Canadian Biomarker Integration Network in Depression
Investigators  ICMJE
Principal Investigator: Sidney H Kennedy, MD St. Michael's Hospital, Toronto
PRS Account St. Michael's Hospital, Toronto
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP